

PRECIS-2 can assess pragmatic aspects of ongoing cervical cancer screening trials to generate implementation evidence

Prajakta Adsul¹, Sylvaine Barbier², Maryluz Rol², Armando Baena², Maribel Almonte²

1. Assistant Professor, University of New Mexico, Albuquerque, NM 87103 (padsul@salud.unm.edu); 2. Prevention and Implementation Group, International Agency for Research on Cancer, Lyon, 69372 France

GROWING BURDEN OF CERVICAL CANCER

- Low- and middle-income countries across the globe are seeing a rising incidence in cervical cancer (1)
- Urgent need to promote evidence-based screening interventions, but very limited information on how best to implement these interventions in these low-resource contexts
- ESTAMPA is a multi-centric screening and triage study recruiting 50,000 women aged 30-64 years, in 12 sites from 9 Latin American countries [Argentina, Colombia, Paraguay, Bolivia, Costa Rica, Honduras, Mexico, Peru and Uruguay] (2)
- Designed to fit within the context of each country site and with an emphasis on reaching underserved populations, this trial provides a unique opportunity to assess pragmatic aspects of the screening and triage programs and generate implementation evidence using the Pragmatic Explanatory Continuum Indicator (PRECIS-2) tool (3)

METHODS

- We conducted a facilitated group discussion with the primary coordinating team and based on team consensus scored the ESTAMPA trial on the nine domains
- In addition, we surveyed study teams (n=107) using previously validated measures (4) to assess acceptability, appropriateness, and feasibility of conducting the screening process in their context.

RESULTS

- Fig 1, shows the scores for the nine domains in the PRECIS-2 wheel, highlighting the pragmatic aspects of the ESTAMPA trial




Figure 1. PRECIS-2 wheel for ESTAMPA

- Fig 2 shows, the percent of individuals reporting agreement on the 12-item survey with 4 questions about acceptability [intervention meets my approval, appealing to me, I like the intervention, I welcome the intervention], appropriateness [the intervention seems fitting to me, suitable for my organizations, applicable in my organization, good match for my organization], and feasibility [intervention is implementable in my organization, possible in my organization, doable in my organization, and easy to use in my organization] each.




Figure 2. Acceptability, appropriateness, and feasibility, as reported by the study staff and primary investigators at ESTAMPA sites

WORKS IN PROGRESS

- Ongoing data collection with site-specific teams, on PRECIS-2 domains with qualitative data
- Ongoing qualitative data on acceptability, appropriateness, and feasibility from site-teams
- Examine associations with screening uptake and follow-up rates

REFERENCES

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians*. 2018;68(6):394-424.
2. Almonte M, Murillo R, Sánchez GI, González P, Ferrera A, Picconi MA, et al. Multicentric study of cervical cancer screening with human papillomavirus testing and assessment of triage methods in Latin America: the ESTAMPA screening study protocol. *BMJ Open*. 2020;10(5):e035796.
3. Loudon K, Treweek S, Sullivan F, Donnan P, Thorpe KE, Zwarenstein M. The PRECIS-2 tool: designing trials that are fit for purpose. *BMJ : British Medical Journal*. 2015;350:h2147.
4. Weiner BJ, Lewis CC, Stanick C, Powell BJ, Dorsey CN, Clary AS, et al. Psychometric assessment of three newly developed implementation outcome measures. *Implementation Science*. 2017;12(1):108.